Abstract
An important component of tumor progression is the generation of “survival signals” that suppress default apoptotic programs. Survival signals are ideal targets for anticancer therapeutic strategies because blocking survival signals, in principle, can resurrect the apoptotic signals that are suppressed in cancer cells. Phospholipase D (PLD) activity, which is elevated in a large variety of cancers, generates a survival signal that has been shown to suppress apoptosis in human breast cancer cells. Phosphatidic acid, the metabolic product of PLD activity, contributes to the activation of mTOR (the mammalian target of rapamycin), which has been widely implicated in cancer survival signals. Elevated PLD activity suppresses the tumor suppressors p53, Rb and protein phosphatase 2A, and also causes Myc stabilization - indicating that PLD activity is a key regulator of the cellular machinery that controls cell cycle progression. The ability of PLD to suppress apoptosis makes PLD signal transduction an ideal target for therapeutic intervention in the apparent large number of cancers that have elevated PLD activity. As the era of molecular medicine and pathology evolves, it will be possible to identify individual tumors with elevated PLD activity and target either the signals that activate PLD or the downstream targets of PLD. In this review, the emerging paradigm of PLD survival signals is discussed in the context of therapeutic intervention.
Keywords: Survival signals, apoptosis, phospholipase D, rapamycin, mTOR, tumorigenesis
Current Signal Transduction Therapy
Title: Targeting Phospholipase D-mediated Survival Signals in Cancer
Volume: 1 Issue: 3
Author(s): David A. Foster
Affiliation:
Keywords: Survival signals, apoptosis, phospholipase D, rapamycin, mTOR, tumorigenesis
Abstract: An important component of tumor progression is the generation of “survival signals” that suppress default apoptotic programs. Survival signals are ideal targets for anticancer therapeutic strategies because blocking survival signals, in principle, can resurrect the apoptotic signals that are suppressed in cancer cells. Phospholipase D (PLD) activity, which is elevated in a large variety of cancers, generates a survival signal that has been shown to suppress apoptosis in human breast cancer cells. Phosphatidic acid, the metabolic product of PLD activity, contributes to the activation of mTOR (the mammalian target of rapamycin), which has been widely implicated in cancer survival signals. Elevated PLD activity suppresses the tumor suppressors p53, Rb and protein phosphatase 2A, and also causes Myc stabilization - indicating that PLD activity is a key regulator of the cellular machinery that controls cell cycle progression. The ability of PLD to suppress apoptosis makes PLD signal transduction an ideal target for therapeutic intervention in the apparent large number of cancers that have elevated PLD activity. As the era of molecular medicine and pathology evolves, it will be possible to identify individual tumors with elevated PLD activity and target either the signals that activate PLD or the downstream targets of PLD. In this review, the emerging paradigm of PLD survival signals is discussed in the context of therapeutic intervention.
Export Options
About this article
Cite this article as:
Foster A. David, Targeting Phospholipase D-mediated Survival Signals in Cancer, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226941
DOI https://dx.doi.org/10.2174/157436206778226941 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review
Current Drug Targets HPLC Analysis of Phenolic Acids, Antioxidant Activity and in vitro Effectiveness of Green and Roasted Caffea arabica Bean Extracts: A Comparative Study
Anti-Cancer Agents in Medicinal Chemistry Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Central Nervous System Agents in Medicinal Chemistry Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Radiologic Findings of a Rare Subtype of Invasive Breast Cancer with Poor Prognosis: Metaplastic Carcinoma of the Breast
Current Medical Imaging Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
Current Topics in Medicinal Chemistry How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments
Current Drug Metabolism Evaluation of a New <sup>99m</sup>Tc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Elderly Cancer Patients in the 3rd Millenium: Between Hope and Reality. Introduction)
Anti-Cancer Agents in Medicinal Chemistry Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Current Medicinal Chemistry Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Novel Carriers for Controlled Site Specific Delivery of Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib
Current Drug Delivery Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Synthesis and Biological Evaluation of New Naphthoquinones Derivatives
Current Organic Synthesis